Sofie Biosciences unveils preclinical PET unit
Sofie Biosciences has launched a preclinical PET unit that facilities can use to identify and evaluate new cancer and inflammation probes.

The Culver City, Calif.-based company touts the device as a low-cost imaging system capable of organ-level tissue quantification.

The firm said the system has "significant value in being able to rapidly label a small molecule or biological and carry out a low-cost high-sensitivity biodistribution assay, prior to imaging with a high resolution PET or PET/CT system."